Table 1:

Baseline clinical and demographic characteristics

Total Sample (n = 37)
Demographic characteristics
Female (No.) (%)21 (56.8)
Age at moyamoya diagnosis (median) (IQR, 25–75) (yr)10 (6.3–11.8)
Age at initial CVR (median) (IQR, 25–75) (yr)10.7 (7.5–14.7)
Time to follow-up (median) (IQR, 25–75) (mo)20.8 (13.7–84.1)
Moyamoya classification
    Idiopathic14 (37.8)
    Syndromic23 (62.2)
     NF19 (24.3)
     Trisomy 21/other chromosomal disorders7 (18.9)
     Sickle cell disease5 (13.5)
     Postradiation vasculopathy2 (5.4)
Clinical presentation
    Stroke (No.) (%)12 (32.4)
     Bilateral2 (5.4)
     Right6 (16.2)
     Left4 (10.8)
    TIA (No.) (%)8 (21.6)
    Seizure (No.) (%)3 (8)
    Headaches (No.) (%)8 (21.6)
    Asymptomatic (No.) (%)6 (16.2)
    Other (No.) (%)2 (5.4)
Radiographic findings (No.) (%)
    Parenchymal
     Not ischemic8 (21.6)
     Watershed12 (32.4)
      Deep white matter1 (2.7)
      Cortical12 (32.4)
    Cortical3 (8.1)
    Cortical ischemic and watershed14 (37.8)
    Vascular
     Moyamoya laterality (No.) (%)
      Left8 (21.6)
      Right6 (16.2)
      Bilateral23 (62.2)
    Grade of stenosis (No.) (%)
    50%–74% Occlusion5 (13.5)
    ≥75% Occlusion32 (86.5)

  • Note:—NF1 indicates neurofibromatosis type 1.